Due to its biosafety, current worldwide approved nonviral gene products have been mainly focused on the administration of naked pDNA molecules encoding for angiogenic factors (pDNA-HGF: Collategene [122]; pDNA-VEGF: Neovasculgen [123]) for the treatment of cardiovascular diseases [124]. Here, HGF is linked to cardiovascular disorder.